Search Results - "Weekes, C.D."

450O Initial monotherapy results of a phase I first-in-human study of ULK1/2 inhibitor DCC-3116 alone and in combination with MAPK pathway inhibition by Tolcher, A.W., Hong, D.S., Vandross, A., Amaravadi, R., Psoinos, C., Brennan, D., Sherman, M.L., Ruiz-Soto, R., Viswanathan, L., Sprott, K., Reu, F.J., Weekes, C.D.

Get full text

664P Final results of a phase I/II study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors by Corcoran, R.B., Do, K.T., Cleary, J., Parikh, A., Yeku, O., Weekes, C.D., Ahronian, L., Mauri, G., Tian, J., Brugge, J., Juric, D., Flaherty, K.T., Sullivan, R.J., Clark, J., Heist, R., Matulonis, U.A., Liu, J.F., Shapiro, G.I.

Get full text

1470P Oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence by Heumann, T.R., Baretti, M., Sugar, E., Durhman, J., Liden, S., Miles, T., Lopez-Vidal, T.Y., Leatherman, J., Sharma, A., Ahuja, N., Weekes, C.D., O'Dwyer, P.J., Monga, D.K., Reiss Binder, K.A., Azad, N.

Get full text

Phase I/II study of combined BCL-XL and MEK inhibition with navitoclax (N) and trametinib (T) in KRAS or NRAS mutant advanced solid tumours by Corcoran, R.B., Do, K.T., Cleary, J.M., Parikh, A.R., Yeku, O.O., Weekes, C.D., Veneris, J., Ahronian, L.G., Mauri, G., Van Seventer, E.E., Fetter, I.J., Gurski, J.M., Matulonis, U.A., Juric, D., Flaherty, K.T., Sullivan, R.J., Clark, J.W., Heist, R.S., Shapiro, G.I.

Get full text

447PD - Phase I/II study of combined BCL-XL and MEK inhibition with navitoclax (N) and trametinib (T) in KRAS or NRAS mutant advanced solid tumours by Corcoran, R.B., Do, K.T., Cleary, J.M., Parikh, A.R., Yeku, O.O., Weekes, C.D., Veneris, J., Ahronian, L.G., Mauri, G., Van Seventer, E.E., Fetter, I.J., Gurski, J.M., Matulonis, U.A., Juric, D., Flaherty, K.T., Sullivan, R.J., Clark, J.W., Heist, R.S., Shapiro, G.I.

“…MEK inhibitors (MEKi) lack single agent clinical efficacy in RAS mutant cancers, likely because MEKi produce only a cytostatic response in preclinical RAS…”
Get full text

Refametinib by Lammers, A., Weekes, C.D.

Get full text

Refametinib by Lammers, A., Weekes, C.D.

Get full text